Figure 1. Overall survival of the 61 patients enrolled in the study.Top. Five-year probability of survival was 76% (95% CI, 64% to 88%). Dotted lines represent the upper and lower boundaries of confidence intervals. Bottom. Covariate-adjusted survival for responders and nonresponders. Response status was ascertained at 8 months after treatment with antithymocyte globulin.